Dually-Listed Healthcare Stock Rallies On Q1 Results

Sponsored:

Wednesday, May 17, 2023

A Canadian medical diagnostics & screening company found tremendous success during Wednesday’s session just one session following the company’s Q1 2023 financial results.

Traders couldn’t get their hands on shares of this micro cap after StageZero Life Sciences Ltd. (TSX:SZLS) (OTCQB:SZLSF) disclosed a 15.2% growth in revenue quarter to quarter. According to the press release, a few other operational updates and highlights for the first three months of 2023 are as follows:

- Generated $0.779 Million revenue for the quarter (an increase of 15.2% over last Quarter Q4 2022)
- Launched COC Protocol 2 in the US and Canada. Initial uptake very positive.
- METRICS Study Informs Expansion of StageZero's New Care Oncology Protocol 2; pathway to METRICS II and Glioblastoma addition to Aristotle®.
- COC clinics on path to full profitability by end Q3.
- Initiating mental health support program for Care Oncology patients and for employer groups. Launch in Q2.
- Scaled up Aristotle®/AVRT early cancer screening with Fire Fighters in the Greater Toronto Area.
- Aristotle® Employer programs gaining traction.

Shares trading on the Canadian side reached up to $0.06/share (+9.09%) at the session high.

StageZero Life Sciences Ltd is a Canadian company, focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. It develops a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. Its lead product, ColonSentry is a blood test to determine the patient's current risk of having colorectal cancer.

Sponsored: